Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer

TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.

Trial Details

NCT ID
NCT05377047
Phase
PHASE3
Sponsor
Vastra Gotaland Region
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • SABR
Locations (sample)
  • Cork, Ireland|51.89797,-8.47061
  • Cork, Ireland|51.89797,-8.47061
  • Dublin, Ireland|53.33306,-6.24889
  • Galway, Ireland|53.27245,-9.05095
  • Tel Aviv, Israel|32.08088,34.78057

Key Eligibility Criteria

  • Histologically or cytological confirmed recurrent OMBC.
  • Age ≥18 years old.
  • OMBC defined as 1-5 metastases in a maximum of two organs confirmed by PET-CT.
  • Patients already on 1st line systemic treatment can be enrolled if repeated tumour evaluations show stable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →